medigraphic.com
ISSN 1817-5996 (Electronic)

2020, Number 1

<< Back Next >>

Rev Cub de Reu 2020; 22 (1)

Gamma glutamyl transferase: an indicator of medical ozone clinical efficacy and its pathological role in rheumatoid arthritis and knee osteoarthritis

León FOS, Takon OG, López CG, Serrano EI, García FE

Language: Spanish
References: 26
Page: 1-18
PDF size: 414.02 Kb.


ABSTRACT

Introduction: Medical ozone has demonstrated its clinical efficacy as well as the increase of beneficial/risk relationship in rheumatoid arthritis patients treated with metotrexate+ozone combined therapy. At present, gamma-glutamyl transpeptidase is considered as risk indicator of high morbimortality diseases. It has a special value in arthritis diseases due to its pathologic role associated to oxidative stress and in the abnormal bone remodeling processes.
Objective: Assess the ozone medical effects on gamma-glutamyl transpeptidase levels.
Method: Patients who suffered of two arthritic diseases: rheumatoid arthritis (n=100; Group treated with Metotrexate (n=50) and metotrexate+ozone (n=50) and knee osteoarthritis (n=40); Group preconditioned with ozone before arthroscopy (n=20) and Group without previous treatment with ozone before arthroscopy (n=20). Rheumatoid arthritis patients were assessed through specific clinic indicators which included antibodies against cyclic citrullinate peptides as well as reduced gluthatione concentrations which are an important endogenous antioxidant.
Results: Medical ozone regulated serum gamma-glutamyl transpeptidase activity which correlated in inverse proportion to reduced glutathione levels which was the only one redox marker that correlated with all clinical variables (p < 0.05) when patients were treated with metotrexate+ozone.
Conclusion: Gamma-glutamyl transpeptidase should be considered as biomarker of medical ozone clinical efficacy in rheumatoid arthritis and knee osteoarthritis due to GGT´s both pathologic functions: indicator of oxidative stress and abnormal bone remodeling processes.


REFERENCES

  1. Zhang H, Forman HJ, Choi J. Gamma-glutamyl transpeptidase in glutathione biosynthesis. Methods Enzymol. 2005;401:468-83.

  2. Fraser A, Harris R, Sattar N, Ebrahim S, Smith GD, Lawlor DA. Gamma-glutamyl transferase is associated with incident vascular events independently of alcohol intake: analysis of the Brithish Women´s Heart and Health Study and Meta-analysis. Arterioscler Throm Vasc Biol. 2007;27:2729-35.

  3. Lee DH, Silventoinen K, Jacobs DR Jr, Jousilahti P, Tuomileto J. Gamma-Glutamyl transferase, obesity and the risk of typle 2 diabetes: observational cohort study among 20,158 middle-aged men and women. J. Clin Endocrinol Metab. 2004;89:5410-4.

  4. Ruttmann E, Brant LJ, Concin H, Diem G, Rapp K, Ulmer H. Gamma-glutamyl transferase as a risk factor for cardiovascular disease mortality: an epidemiological investigation in a cohort of 163 944 Austrian adults. Circulation. 2005;112:2130-7.

  5. Gerald K, Stephanie S. Gamma-Glutamyl transferase: A predictive biomarker of cellular antioxidant inadequacy and disease risk. Disease Markers; 2015 [Internet]. [Acceso 01/07/2019] 2015. Disponible en http://dx.doi.org/10.1155/2015/818570

  6. Han SCh, Kwang JK, Yumie R, Sung-Kil L. Serum g-Glutamyl transferase is inversely associated with bone mineral density independently of alcohol consumption. Endocrinol Metab. 2016;31:64-71.

  7. Sawako M, Takeshi I, Keiko S, Mutsumi M, Takashi T, Keigo S, et al. γ-Glutamyl transpeptidase is an endogenous activator of Toll-like receptor 4-mediated osteoclastogenesis. Scientific Repo. 2016;6:35930.

  8. Takayanagi H. Osteoimmunology: shared mechanisms and crosstalk between the immune and bone systems. Nat Rev Immunol. 2007;7:292-304.

  9. Hiramatsu K, Asaba Y, Takeshita S, Nimura Y, Tatsumi S, Katqagiri N. Overexpression of gamma glutamyl transferase in transgenic mice accelerates bone resorption and causes osteoporosis. Endocrin. 2007;148:2708-15.

  10. Asaba Y, Hirmatsu K, Matsui Y, Harada A, Nimura Y, Katagiri N. Urinary gamma galutamyl transferase (GGT) as a potential marker of bone resorption. Bone. 2006;39:1276-82.

  11. León Fernández OS, Viebahn-Haensler R, López Cabreja, Serrano Espinosa I, Hernández Matos Y, Delgado Roche L, et al. Medical ozone increases methotrexate clinical response and improves cellular redox balance in patients with rheumatoid arthritis. Eur J of Pharmacol. 2016;789:313-8.

  12. World Medical Association Declaration of Henlsinki, 2005. Ethical Principles for Medical Research involving Human subjects. [Acceso 12/05/2019] 2005. Disponible en: www.bioethics.nih.gov/international/declarat/helsinki.rtf

  13. Research Randomizer Form v 4.0 [Internet]. [Acceso 08/04/2019] 2019. Disponible en: www.randomizer.org/form.htm

  14. Levy PS, Lemenshow S. Sampling of Populations. Methods and Applications John. New Jersey: Ed. Wiley & Sons; 1991.

  15. Arnett FC, Edworthy SM, Bloch DA, Mc Shane DJ, Fries JF, Coopler NS, et al. The American Rheumatism Association 1987 revised criteria for the classification or rheumatoid arthritis. Arthritis Rheumatol. 1988;31:315-24.

  16. Cardiel MH, Abello-Banfi M, Ruiz-Mercado R, Alarcón-Segovia D. How to measure health status in rheumatoid arthritis in non-English speakin patients: validation of a Spanish version of the Health Assessment Questionnaire Disability Index (Spanish HAQ-DI). Clin Exp Rheumatol. 1993;11:117-21.

  17. Sedlak J, Lindsay RH, Estimation of total protein. Bound and nonprotein sulfhydryl groups in tissue with Ellman´s reagent. Anal Bochem. 1968;25:192-205.

  18. Meenakshi S, Adinath NS, Nitin HU. Is gamma-glutamyl transpeptidase a biomarker for oxidative stress in periodontitis? J Indian Soc Periodontol. 2015;19:150-4.

  19. Toru I. Molecular hydrogen: New antioxidant and anti-inflammatory therapy for rheumatoid arthritis and related diseases. Current Pharm Design. 2013;19:6375-81.

  20. Zaidi M. Skeletal remodeling in health and disease. Nat Med. 2007;13:791-801.

  21. Iida M, Yasuhara T, Mochizuki H, Takakura H, Yanagisawa T, Kubo H. Two Japanese brothers with hereditary gamma glutamyl transpeptidase deficiency. J Inherit Metab Dis. 2005;28:49-55.

  22. Ristoff E, Larsson A. Inborn errors in the metabolism of glutathione. Orphanet J Rare Dis. 2007;2:16-20.

  23. Levasseur R, Barrios R, Elefteriou F, Glass DA, Lieberman MW, Karsenty G. Reversible skeletal abnormalities in gamma-glutamyl transpeptidase-deficient mice. Endocrinol. 2003;144:2761-4.

  24. Kazemi-Shirazi L, Endler G, Winkler S, Schickbatter T, Wagner O, Marsik C. Gamma glutamyltransferase and long term survival: is it just the liver? Clin Chem. 2007;5:940-6.

  25. Lee DH, Ha MH, Kam S. A strong secular trend in serum gamma-glutamyl transferase from 1996-2003 among South Korean men. Am J of Epidemiol. 2006;163:57-65.

  26. Aydin, Ilkcan C, Dogan E, Karaca Z, Koçyiğit I, Sipahioğlu MH, et al. Gamma-Glutamyl Transferase is related to microalbuminuria in diabetic patients. Turkish Nephrology, Dialysis and Transplantation Journal. 2014;23(3):217-22.




2020     |     www.medigraphic.com